Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $18.8 million.

  • Anika Therapeutics' Operating Expenses fell 344.81% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 6724.78%. This contributed to the annual value of $81.1 million for FY2024, which is 72.1% down from last year.
  • Per Anika Therapeutics' latest filing, its Operating Expenses stood at $18.8 million for Q3 2025, which was down 344.81% from $18.5 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Operating Expenses peaked at $35.4 million during Q1 2023, and registered a low of -$18.9 million during Q4 2023.
  • Over the past 5 years, Anika Therapeutics' median Operating Expenses value was $21.5 million (recorded in 2024), while the average stood at $19.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 14632.94% in 2022, then soared by 19419.94% in 2024.
  • Over the past 5 years, Anika Therapeutics' Operating Expenses (Quarter) stood at $27.3 million in 2021, then plummeted by 146.33% to -$12.6 million in 2022, then plummeted by 49.9% to -$18.9 million in 2023, then skyrocketed by 194.2% to $17.8 million in 2024, then grew by 5.53% to $18.8 million in 2025.
  • Its last three reported values are $18.8 million in Q3 2025, $18.5 million for Q2 2025, and $19.0 million during Q1 2025.